Binding of glucagon to its receptor, GCGR, results in an increase in intracellular cAMP levels, which plays a role in promoting glycogenolysis and gluconeogenesis, altogether elevating blood glucose levels.
Biocytogen generated a humanized B-hGCGR mouse model; human GCGR protein and mRNA expression was confirmed in B-hGCGR mice.
Anti-human GCGR antibody treatment reduced random blood glucose and fasting blood glucose levels, and improved glucose tolerance.
Anti-human GCGR antibody treatment blocked the functional response to glucagon in B-hGCGR mice with increased efficiency compared to targeting the wild-type murine receptor using antagonists.
B-hGCGR mice are a promising model for preclinical in vivo pharmacodynamic assessment of anti-GCGR antibodies.
Share:
We use cookies to personalize content, analyze traffic, and ensure that we give you the best experience on our website. Click To Continue
